Molecular biology reports · 2025
Exploring the role of Myo-inositol in alleviating insulin resistance in polycystic ovary syndrome through the AMPK/GLUT4 pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Song Guihong, Liu Nannan, He Jiajin, Tang Saisai, Yu Yiping, Song Lihua
Аннотация
BACKGROUND: Polycystic ovary syndrome (PCOS) is a multifactorial disorder associated with insulin resistance, hyperandrogenism, and metabolic dysfunction. Myo-inositol, a promising therapeutic alternative, may improve glucose and lipid metabolism through the 5'-adenosine monophosphate-activated protein kinase (AMPK)-glucose transporter type 4 (GLUT4) pathway. This study aimed to investigate the molecular and metabolic effects of Myo-inositol in a letrozole-induced rat model of PCOS.
METHODS AND RESULTS: We divided rats into six groups: controls, PCOS, and different doses of Myo-inositol- or metformin-treated groups. We examined the rat blood glucose, insulin, lipid profiles, and hormone levels alongside ovarian histology and AMPK/GLUT4 expression via polymerase chain reaction and western blotting assays. Myo-inositol treatment demonstrated dose-dependent improvements in glucose homeostasis, lipid profiles, and GLUT4 expression, with high-dose treatment reducing glucose by 0.85-fold and improving lipid metabolism compared to metformin treatment. Ovarian histology revealed partial restoration of follicular development, and AMPK activation supported enhanced glucose uptake.
CONCLUSIONS: Myo-inositol effectively alleviated insulin resistance and metabolic dysfunction, offering a promising alternative to conventional PCOS treatments.
METHODS AND RESULTS: We divided rats into six groups: controls, PCOS, and different doses of Myo-inositol- or metformin-treated groups. We examined the rat blood glucose, insulin, lipid profiles, and hormone levels alongside ovarian histology and AMPK/GLUT4 expression via polymerase chain reaction and western blotting assays. Myo-inositol treatment demonstrated dose-dependent improvements in glucose homeostasis, lipid profiles, and GLUT4 expression, with high-dose treatment reducing glucose by 0.85-fold and improving lipid metabolism compared to metformin treatment. Ovarian histology revealed partial restoration of follicular development, and AMPK activation supported enhanced glucose uptake.
CONCLUSIONS: Myo-inositol effectively alleviated insulin resistance and metabolic dysfunction, offering a promising alternative to conventional PCOS treatments.